Current Problems in Cardiology
Volume 32, Issue 6 , Pages 321-366 , June 2007

Management of Acute Decompensated Heart Failure

References 

  1. American Heart Association; American Stroke Association. Heart disease and stroke statistics—2005 update. Available at: http://www.americanheart.org/downloadable/heart/1072969766940Hstats2004Update.pdf. Accessed December 1, 2005.
  2. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends with the incidence and survival with heart failure. New Engl J Med. 2002;347:1397–1402
  3. Adams KF. New epidemiologic perspectives concerning mild-to-moderate heart failure. Am J Med. 2001;110(supp 7A):6S–13S
  4. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:1116–1143
  5. Fonarow GC ADHERE Scientific Advisory Committee. The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21–S30
  6. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Inter Med. 1997;157:99–104
  7. Polanczyk CA, Rohde LE, Dec GW, et al. Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch Intern Med. 2000;160:325–332
  8. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction (Mortality, readmission, and functional decline). J Am Coll Cardiol. 2003;41:1510–1518
  9. Felker GM, Adams KF, Konstam MA, et al. The problem of decompensated heart failure: nomenclature, classification risk stratification. Am Heart J. 2003;143(suppl):S18–S25
  10. Gheorghiade M, Bebazaa A. Introduction to acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):1G–4G
  11. Nieminen MS, Harjola V-P. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):5G–10G
  12. Gheorghiade M, DeLuca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):11G–17G
  13. Ware LB, Matthay MA. Acute pulmonary edema. New Engl J Med. 2005;353:2788–2796
  14. Harlan WR, Oberman A, Grimm R, et al. Chronic congestive heart failure in coronary artery disease: clinical criteria. Ann Intern Med. 1997;86:133–138
  15. Stevenson LW, Perloff JK. Limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884–888
  16. Badgett RG, Lucey CR, Mulrow CE. Can the clinical examination diagnose left-sided heart failure in adults?. JAMA. 1997;277:1712–1719
  17. Yancy CW. Heart failure in African Americans: a cardiovascular enigma. J Card Fail. 2000;6:183–186
  18. Adams KF, Lindenfeld JA, Arnold JMO, et al. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guidelines. J Card Fail. 2006;12:10–38
  19. Maytin M, Colucci WS. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):26G-31
  20. Perna ER, Macin SM, Parras JI, et al. Cardiac troponin levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J. 2002;143:814–820
  21. Eichhorn EJ. Prognosis determination in heart failure. Am J Med. 2001;110(7A):14S–35S
  22. Ho KKL, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in the Framingham Heart Study subjects. Circulation. 1993;88:107–115
  23. Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. New Engl J Med. 2001;345:574–581
  24. Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol. 2003;91:538–543
  25. Koelling TM, Aaronson KD, Cody RJ, et al. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J. 2002;144:373–376
  26. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–7
  27. Harajai KJ, Tompson HW, Turget T, et al. Simple clinical variables are markers for propensity for readmission in patients hospitalized with heart failure. Am J Cardiol. 2001;87:234–237
  28. Chin MW, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med. 1996;156:1814–1820
  29. Klein L, O’Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure. Circulation. 2005;111:2454–2460
  30. Jong P, Vowinckel E, Liu P, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure. Arch Intern Med. 2002;62:1689–1694
  31. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12,220 index admissions in Leicestershire 1993-2001. Heart. 2003;89:615–620
  32. Felker GM, Benza RL, Chandler AB, et al. OPTIME-CHF Investigators Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997–1003
  33. Felker GM, Gattis WM, Leimberger JD, et al. Usefulness of anemia as a predictor of death and re-hospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625–628
  34. Logeart D, Thabut G, Jourdain P, et al. Pre-discharge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635–641
  35. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-BNP natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168–2174
  36. Gheorghiade M, Zannad F, Supko G, et al. International Working Group on Acute Heart Failure Syndromes Acute heart failure syndromes (Current state and framework for future research). Circulation. 2005;112:3958–3968
  37. Horwich TB, Patel J, MacLellan WR, et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality in advanced heart failure. Circulation. 2003;108:833–838
  38. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004;10:460–466
  39. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation and survival in patients with chronic heart failure. Circulation. 2000;102:203–210
  40. Weinfield MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138:285–290
  41. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136–141
  42. Fonarow GC, Adams KF, Abraham WT, et al. ADHERE Scientific Advisory Committee, Study Groups and Investigators Risk stratification for in-hospital mortality in acutely decompensated heart failure Classification and regression tree analysis. JAMA. 2005;293:572–580
  43. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287:628–640
  44. Nohria A, Tsant SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797–1804
  45. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail. 1999;1:251–257
  46. Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997;96:1165–1172
  47. ESCAPE Investigators and Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (The ESCAPE trial). JAMA. 2005;294:1625–1633
  48. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J. 1998;135:S293–S309
  49. Dec GW. Acute decompensated heart failure (The shrinking role of inotropic therapy). J Am Coll Cardiol. 2005;46:65–67
  50. Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):32G–40G
  51. Brater DC. Diuretic therapy. New Engl J Med. 1998;339:387–395
  52. Stough WG, O’Connor CM, Gheorghiade M. Overview of current non-inodilator therapies for acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):41G–46G
  53. Abraham WT, Adams KF, Fonarow GC, et al. ADHERE Scientific Advisory Committee and Investigators ADHERE Study group In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications (An analysis form the Acute Decompensated Heart Failure National Registry (ADHERE)). J Am Coll Cardiol. 2005;46:57–64
  54. Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28:376–382
  55. Costanzo MR, Saltzberg M, O’Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46:2047–2051
  56. Weber KT. Aldosterone in congestive heart failure. New Engl J Med. 2001;345:1689–1697
  57. Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med. 1999;341:709–717
  58. White H, Nicolau J, Martinez F, et al. EPHESUS Investigators Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425–431
  59. Hauptman PJ, Kelly RA. Digitalis. Circulation. 1999;99:1265–1270
  60. Dec GW. Digoxin is useful in the management of chronic heart failure. Med Clin N Am. 2003;87:317–337
  61. Newton GE, Tong JH, Schofield AM, et al. Digoxin reduces cardiac sympathetic activity in severe heart failure. J Am Coll Cardiol. 1996;28:155–161
  62. Lee DCS, Johnson RA, Bingham JB, et al. Heart failure in outpatients (A randomized trial of digoxin versus placebo). New Engl J Med. 1982;306:699–705
  63. Gheorghiade M, Hall V, Lakier JB, et al. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combination in patient with severe heart failure. J Am Coll Cardiol. 1989;13:134–142
  64. Gheorghiade M, Adams KF, Colucci W. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959–2964
  65. Rathorne SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. New Engl J Med. 2002;347:1403–1411
  66. Adams KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigator Group trial (A retrospective analysis). J Am Coll Cardiol. 2005;46:497–504
  67. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558–569
  68. Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: a review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Therapeut. 2004;9:243–255
  69. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation. 2003;107:1570–1575
  70. Fonarow GC. Role of in-hospital initiation of carvedilol to improve treatment rates and clinical outcomes. Am J Cardiol. 2004;93(suppl):77B–81B
  71. Packer M, Coates AJ, Fowler MB, et al. Carvedilol Prospective Cumulative Survival Study group Effect of carvedilol on survival in severe heart failure. New Engl J Med. 2001;344:1651–1658
  72. Gattis W, O’Connor CM, Gallup DS, et al. Pre-discharge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the IMPACT-HF (initiation management pre-discharge process for assessment of carvedilol therapy in heart failure) trial. J Am Coll Cardiol. 2003;43:1534–1541
  73. Metra M, Nodari S, D’Alaia AK, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure (A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol). J Am Coll Cardiol. 2002;40:1248–1258
  74. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998;31:1336–1340
  75. Packer M, Poole-Wilson PA, Armstrong PW, et al. ATLAS Group Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312–2318
  76. Cotter G, Metzkor E, Kaluski E, et al. Randomized trial of high-dose isosorbide dinitrate plus low dose furosemide versus high-dose furosemide and low dose isosorbide dinitrate in severe pulmonary edema. Lancet. 1998;351:389–393
  77. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. New Engl J Med. 2001;344:1351–1357
  78. Taylor AL, Ziesche S, Yancy C, et al. African-American Heart Failure Trial Investigators Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New Engl J Med. 2004;351:2049–2057
  79. Nieminen MS, Bohm , Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416
  80. Guiha NH, Cohn JN, Mikulic E, et al. Treatment of refractory heart failure with infusion of nitroprusside. New Engl J Med. 1974;291:587–592
  81. Khot UN, Novaro GM, Popvic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. New Engl J Med. 2003;348:1756–1763
  82. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators in class IV heart failure. J Am Coll Cardiol. 2002;39:1623–1629
  83. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration Cooperative study. New Engl J Med. 1982;1129–1135
  84. Teerlink JR. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):59G–67G
  85. Wang DJ, Dowling TC, Meadows D. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620–1625
  86. VMAC Publications Committee. Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure (A randomized controlled trial). JAMA. 2002;287:1531–1540
  87. Silver MA, Horton D, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798–803
  88. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  89. Sackner-Bernstein JD, Kowalski MN, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905
  90. Cuffe MS, Califf RM, Adams KR, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  91. Bayram M, DeLuca L, Massie BM, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):47G–58G
  92. Liang CS, Sherman LG, Doherty JU, et al. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation. 1984;69:113–119
  93. Biddle TL, Benotti JR, Creager M, et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol. 1987;59:1345–1350
  94. Eichhorn EJ, Konstam MA, Weiland DS, et al. Differential effects of milrinone and dobutamine on right ventricular preload, afterload, and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1987;60:1329–1333
  95. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? (Part I: inotropic infusions during hospitalization). Circulation. 2003;108:367–372
  96. Nerheim P, Birger-Botkin S, Piracha L, et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy. Circulation. 2004;110:247–252
  97. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for treatment. Am J Cardiol. 2003;91:2D–8D
  98. Torp-Pederson , Moller M, Bloch-Thomsen PE, et al. Danish Investigators of Arrhythmia and Mortality on Dofetilide Study Group Dofetilide in patients with congestive heart failure and left ventricular dysfunction. New Engl J Med. 1999;341:857–865
  99. Strickberger SA, Conti J, Daoud EG, et al. Patient selection for cardiac resynchronization therapy. Circulation. 2005;111:2146–2150
  100. Abraham WT, Hayes DL. Cardiac resychronization therapy for heart failure. Circulation. 2003;108:2596–2603
  101. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation. 2003;108:2184–2190
  102. Aaronson D, Burger AJ. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol. 2003;91:245–248
  103. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2003;42:140–147
  104. Coletta AP, Cleland JP. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology: WARIS II, ESCAMI, PAFAC, RITZ-1, and TIME. Eur J Heart Fail. 2001;3:747–750
  105. O’Connor CM, Gattis WA, Adams KF, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol. 2003;41:1452–1457
  106. Cotter G, Kaluski E, Stangl K, et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail. 2004;6:601–609
  107. Teerlink JR, McMurray JJ, Bourge RC, et al. VERITAS Investigators Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J. 2005;150:46–53
  108. Packer M. Effects of the endothelin receptor bosentan on the morbidity and mortality in patients with chronic heart failure: results of the ENABLE 1 and 2 trial program. J Am Coll Cardiol. 2002;39:101–102
  109. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohormonal effects of selective endothelin (ET[A]) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002;106:2666–2672
  110. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113:305–315
  111. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81–86
  112. Slawsky MT, Colucci WS, Gottlieb SS, et al. Study Investigators Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102:2222–2227
  113. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet. 2002;360:196–202
  114. Zairis M. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure. J Am Coll Cardiol. 2004;43:206A
  115. Garratt C, Packer M, Colucci W, et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study. Crit Care. 2004;8(suppl 1):89
  116. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Presented at the 2005 American Heart Association Scientific Sessions, Dallas, TX, November 14, 2005.
  117. The SURVIVE-W trial: Comparison of dobutamine and levosimendan on survival in acutely decompensated heart failure. Presented at the 2005 American Heart Association Scientific Sessions, Dallas, TX, November 16,2005.
  118. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785–1791
  119. Orlandi C, Zimmer CA, Gheorghiade M. Role of vasopressin antagonists in the management of acute decompensated heart failure. Curr Heart Fail Rep. 2005;2:131–139
  120. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–2423
  121. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690–2696
  122. Gheorghiade M, Gattis WA, O’Connor CM, et al. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators Effect of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA. 2004;291:1963–1971
  123. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Tolvaptan (EVEREST). J Card Fail. 2005;11:260–269

 The authors have no conflicts of interest to disclose.

PII: S0146-2806(07)00015-1

doi: 10.1016/j.cpcardiol.2007.02.002

Current Problems in Cardiology
Volume 32, Issue 6 , Pages 321-366 , June 2007

Article Tools

* Image Usage & Resolution